Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Jun 25, 2015
U.S. FDA Grants Priority Review for MM-398 New Drug Application

Jun 15, 2015
Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors

Jun 11, 2015
Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer

Jun 1, 2015
Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

Stock Quote (NASDAQ: MACK)


- 0.24

Day High:

Day Low:


4:00 PM ET on Jul 29, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools